Related Experiment Videos

Comparative effects of loratadine and terfenadine on cardiac K+ channels

I Ducic1, C M Ko, Y Shuba

  • 1Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20007, U.S.A.

Insights

Terfenadine significantly blocks cardiac potassium channels, potentially causing QT prolongation. Loratadine and descarboethoxyloratadine show minimal effects on these channels, explaining their lower risk of cardiac events.

Area of Science:

  • Pharmacology
  • Cardiovascular Physiology
  • Molecular Biology

Background:

  • Nonsedating H1-receptor antagonists can affect the QT interval via cardiac K+ channel modulation.
  • Understanding these interactions is crucial for drug safety.

Purpose of the Study:

  • To investigate the effects of terfenadine, loratadine, and descarboethoxyloratadine on various cardiac K+ channels.
  • To determine the molecular basis for observed differences in QT interval effects.

Main Methods:

  • Whole-cell patch-clamp technique on ventricular myocytes and Xenopus oocytes.
  • Assessed effects on inward rectifier (I(Kl)), transient outward (I(to)), maintained (I(ped)), and delayed rectifier (I(Ks), I(Kr)) K+ channels.
  • Utilized therapeutic and higher drug concentrations.

Main Results:

  • Terfenadine significantly suppressed I(Kl), I(Kr), and I(Ks) at higher concentrations.
  • Loratadine and descarboethoxyloratadine showed no significant effects on any K+ channels at therapeutic concentrations.
  • Terfenadine demonstrated a higher affinity for the HERG (I(Kr)) channel compared to loratadine.

Conclusions:

  • Terfenadine's potent blockade of cardiac K+ channels, especially I(Kr), likely contributes to QT prolongation and arrhythmogenesis.
  • Loratadine and descarboethoxyloratadine's lack of significant K+ channel inhibition suggests a safer cardiac profile.

Related Concept Videos